Liquidia (NASDAQ:LQDA) Announces Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Liquidia (NASDAQ:LQDA) released its quarterly earnings data on Wednesday. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.01 by $0.14, Briefing.com reports. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm’s quarterly revenue was up 3072.4% compared to the same quarter last year.

Liquidia Stock Up 3.2%

Shares of NASDAQ:LQDA opened at $36.86 on Wednesday. The firm has a fifty day moving average price of $37.65 and a two-hundred day moving average price of $31.43. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -44.41 and a beta of 0.53. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. Liquidia has a one year low of $11.26 and a one year high of $46.67.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on LQDA shares. Oppenheimer increased their target price on Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research report on Thursday, March 12th. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Needham & Company LLC boosted their price objective on Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. BTIG Research increased their price objective on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, HC Wainwright lifted their target price on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus price target of $42.67.

Insider Buying and Selling

In other Liquidia news, CAO Dana Boyle sold 1,580 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $41.65, for a total value of $65,807.00. Following the transaction, the chief accounting officer directly owned 178,848 shares in the company, valued at $7,449,019.20. This represents a 0.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger Jeffs sold 66,610 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $2,493,212.30. Following the completion of the sale, the chief executive officer directly owned 1,037,528 shares in the company, valued at approximately $38,834,673.04. The trade was a 6.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 212,534 shares of company stock valued at $7,964,719 in the last ninety days. 30.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new stake in Liquidia in the second quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia in the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC increased its holdings in shares of Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares during the last quarter. One68 Global Capital LLC purchased a new stake in shares of Liquidia during the 3rd quarter valued at $227,000. Finally, Ensign Peak Advisors Inc purchased a new stake in shares of Liquidia during the 4th quarter valued at $235,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).